SITC Cancer Immunotherapy Guideline – Lymphoma

SITC Cancer Immunotherapy Guidelines (CIGs) are a collection of clinical practice guidelines developed by multi-disciplinary panels of experts who draw from their own practical experience as well as evidence in the published literature and clinical trial data to develop evidence- and consensus-based recommendations. SITC uses as a model the Institute of Medicine's 2011 "Standards for Developing Trustworthy Clinical Practice Guidelines" to ensure the recommendations are unbiased, transparent and balanced and will aid oncologists in effective clinical decision-making concerning patient selection, toxicity management, response evaluation, and the sequencing or combination of therapies, among other topics.

The SITC consensus statement on immunotherapy for the treatment of lymphoma was developed collaboratively through the efforts of an expert panel that convened to discuss the current therapeutic landscape. Containing consensus recommendations regarding FDA-approved immunotherapies for Hodkin lymphoma and multiple subtypes of non-Hodgkin lymphoma, including rituximab, brentuximab vedotin and axicabtagene ciloleucel, as well as discussion of promising emerging treatment modalities, the clinical practice guideline will provide a valuable resource for the hematology-oncology community.

SITC Lymphoma Immunotherapy Guideline Expert Panel

Members

Sherry Adkins, RN, MSN, CNS, ANP-C — The University of Texas MD Anderson Cancer Center

Stephen M. Ansell, MD, PhD — Mayo Clinic Cancer Center

Joshua Brody, MD — Icahn School of Medicine at Mount Sinai

Mitchell S. Cairo, MD — New York Medical College At Maria Fareri Children's Hospital

Jonathan W. Friedberg, MD, MMSc — University of Rochester Medical Center

Justin P. Kline, MD — University of Chicago

Ronald Levy, MD — Stanford University

David L. Porter, MD — University of Pennsylvania

Koen Van Besien — Weill Cornell Medicine

Michael Werner — Patient Advocate